Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Mankind Pharma Ltd - 543904 - Authorised Key Managerial Personnel To Determine Materiality Of An Event Or Information And Its Disclosure

 Pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please note that the following Key Managerial Personnel of the Company are severally authorised for the purpose of determining the materiality of an event or information to the Stock Exchange(s): 1. Mr. Rajeev Juneja - Vice Chairman & Managing Director 2. Mr. Sheetal Arora - Chief Executive Officer 3. Mr. Arjun Juneja - Chief Operating Officer 4. Mr. Ashutosh Dhawan - Chief Financial Officer The following Key Managerial Personnel of the Company are severally authorised for the purpose of dissemination of material event/information to the Stock Exchange 1. Mr. Ashutosh Dhawan - Chief Financial Officer 2. Mr. Pradeep Chugh - Company Secretary & Compliance Officer
31-05-2023
Bigul

Q4FY23 Quarterly & FY23 Annual Result Announced for Mankind Pharma Ltd.

 Pharmaceuticals company Mankind Pharma announced Q4FY23 & FY23 results: Consolidated Q4FY23: Revenue from Operations at Rs 2,053 crore, up by 19% YoY EBITDA at Rs 419 crore, up by 45% YoY with a margin of 20.4% PAT at Rs 294 crore, up by 52% YoY with a margin of 14.3% EPS of Rs 7.1, up by 50% YoY (FV Re 1) CAPEX of Rs 133 crore Consolidated FY23: Revenue from Operations at Rs 8,749 crore, up by 12% YoY EBITDA at Rs 1,913 crore with a margin of 21.9% PAT at Rs 1,310 crore with a margin of 15.0% EPS of Rs 32.0 (FV Re 1) Cash flow from Operations of Rs 1,813 crore CAPEX of Rs 832 crore Net cash of Rs 1,366 crore Rajeev Juneja, Vice Chairman & Managing Director, said, “The company maintained its strong growth trajectory during the year. Our domestic business continued to outperform the IPM in FY23, led by growth in chronic segments whose share has increased to 34% from 33% in FY22. Our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories. Our focus is on increasing the value of prescription within existing class II-IV and rural markets and increasing penetration in Metros through higher chronic presence. We also plan to leverage our brand dominance to grow our consumer healthcare business, going ahead”. Result PDF
31-05-2023
Bigul

Annual report for Mankind Pharma Ltd. for FY-2023
31-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Disclosure Of Related Party Transaction For The Half Year Ended 31St March, 2023

 Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of related party transactions for the half year ended 31st March, 2023. The disclosure is also being uploaded on the website of the company i.e. www.mankindpharma.com.
30-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation

 In reference to our intimation dated 25th May 2023 under subject 'Intimation of Performance and Business Update Call on Q4FY23 & FY 23 with Senior Management of Mankind Pharma Limited ('the Company')' and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation that would be placed in a Performance and Business update call for Q4FY23 & FY 23 scheduled on Wednesday, 31st May 2023 at 12 noon (IST). The presentation is also being uploaded on the website of the company i.e. www.mankindpharma.com.
30-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), please find enclosed herewith the Press Release on Financial Results of the Company for the quarter and financial year ended on 31st March 2023.
30-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 30Th May 2023

 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023 2. Re-Appointment of M/s. M.K. Kulshrestha & Associates, Cost Accountants as the Cost Auditors of the Company for the Financial Year 2023-24 3. Appointment of Mr. Anil Gupta, Associate Vice President & Head - Internal Audit as the Internal Auditor of the Company with effect from Financial Year 2023-24 in place of retiring Internal Auditor M/s Ghosh Khanna & Co. LLP, Chartered Accountants The disclosure with respect to the point no. 1 already has been submitted to the Stock Exchange through letter dated 30th May 2023 under Subject 'Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023'. The meeting of Board of Directors of the Company commenced at 05:05 p.m. (IST) and concluded at 06:45 p.m. (IST).
30-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended On 31St March 2023

 We are enclosing herewith as follows: a. Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023; b. Auditors' report with unmodified opinion on the audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31st March 2023; and c. The declaration from Chief Financial Officer pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), 2015, Regulations confirming the unmodified opinion of the statutory auditors on the audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31st March 2023. The meeting of Board of Directors of the Company commenced at 05:05 p.m. (IST) and concluded at 06:45 p.m. The above mentioned documents will also be available on the website of the Company at www.mankindpharma.com.
30-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed hereby Annual Secretarial Compliance Report for the financial year ended 31st March, 2023 issued by M/s Dayal & MAUR, Company Secretaries.
29-05-2023
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will host Performance and Business update call on Wednesday, 31st May 2023 at 12 noon (IST) for Q4FY23 & FY23.
25-05-2023
Next Page
Close

Let's Open Free Demat Account